

19 JUL 2005

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/054967 A1

(51) International Patent Classification⁷: C07C 279/12,
281/16, A61K 31/155, A61P 3/10, 3/04

(21) International Application Number:
PCT/IT2003/000792

(22) International Filing Date: 1 December 2003 (01.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
RM2002A000625

17 December 2002 (17.12.2002) IT

(71) Applicant (for all designated States except US): SIGMA
TAU INDUSTRIE FARMACEUTICHE RIUNITE
S.P.A. [IT/IT]; Viale Shakespeare, 47, I-00144 Roma (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GIANNESSI, Fabio
[IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche Riunite
S.P.A., Via Pontina, Km. 30,400, I-00040 Pomezia (IT).
TASSONI, Emanuela [IT/IT]; c/o Sigma-Tau Industrie
Farmaceutiche Riunite S.P.A., Via Pontina, Km 30,400,
I-00040 Pomezia (IT). TINTI, Maria, Ornella [IT/IT];
c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via
Pontina, km 30,400, I-00040 Pomezia (IT). PESSOTTO,
Pompeo [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche
Riunite S.p.A., Via Pontina, Km. 30, 400, I-00040
Pomezia (IT). BOTTA, Maurizio [IT/IT]; c/o Università
di Siena, Dip. Farmaco Chimico Tecnologico, Via Banchi
di Sotto, 55, I-53100 Siena (IT). CORELLI, Federico
[IT/IT]; c/o Università di Siena, Dip. Farmaco Chimico
Tecnologico, Via Banchi di Sotto, 55, I-53100 Siena (IT).

(74) Agent: CAMPANELLI, Domenico; c/o Sigma-Tau
Industrie Farmaceutiche Riunite S.p.A., Via Pontina, km
30,400, I-00040 Pomezia (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VARIOUSLY SUBSTITUTED DERIVATIVES OF GUANIDINE, AND THEIR USE AS MEDICINES WITH ANTI-DIABETES AND/OR ANTI-OBESITY ACTIVITY



(I)

(57) Abstract: Formula (I) compounds are described where the groups are as identified in the text, and their use as medicines, particularly as anti-diabetes, serum glucose-lowering and anti-obesity agents. Said medicines are useful for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, and its complications, syndrome X, the various forms of insulin resistance, and hyperlipidaemias, as well as for the treatment of obesity.

WO 2004/054967 A1